Faculty mentor/PI email address
balog@rowan.edu; forsbemm@rowan.edu
Keywords
Alpha-1 antagonist, adrenergic blockade, nightmare treatment, sleep disturbance, trauma pharmacotherapy, post-traumatic stress disorder
Date of Presentation
5-6-2026 12:00 AM
Poster Abstract
Background: Post-Traumatic Stress Disorder (PTSD) is a prevalent and debilitating condition, and is most often associated with sleep disturbances such as nightmares, flashbacks, and heightened arousal. Prazosin, an alpha-1 adrenergic antagonist, has been widely used for PTSD symptoms, however findings across studies are variable and limited, and the scope of existing evidence is not well established.
Objective: This scoping review aims to systematically map the literature on the use of prazosin in individuals with PTSD across diverse populations, settings, and study designs.
Methods: The scoping review will be conducted in accordance with JBI methodology and reported following PRISMA-ScR guidelines. A comprehensive search will be performed across multiple databases, including PubMed, Embase, PsycINFO, and the Cochrane Library. Studies will be included if they involve individuals diagnosed with PTSD and evaluate prazosin as the therapeutic intervention. All study designs will be included. Animal studies and studies not assessing prazosin in the context of PTSD will be excluded. Title/abstract and full-text screening will be conducted independently by multiple reviewers, with conflicts resolved by a third reviewer. Data will be extracted on study characteristics, population details, intervention use, and reported outcomes.
Expected Significance: This review will provide a comprehensive review of the current literature on prazosin for PTSD, identify gaps in the literature, and inform future research and clinical practice.
Disciplines
Chemicals and Drugs | Medicine and Health Sciences | Mental Disorders
YouTube Video Link
Included in
The Use of Prazosin in Individuals with Post-Traumatic Stress Disorder: A Scoping Review Protocol
Background: Post-Traumatic Stress Disorder (PTSD) is a prevalent and debilitating condition, and is most often associated with sleep disturbances such as nightmares, flashbacks, and heightened arousal. Prazosin, an alpha-1 adrenergic antagonist, has been widely used for PTSD symptoms, however findings across studies are variable and limited, and the scope of existing evidence is not well established.
Objective: This scoping review aims to systematically map the literature on the use of prazosin in individuals with PTSD across diverse populations, settings, and study designs.
Methods: The scoping review will be conducted in accordance with JBI methodology and reported following PRISMA-ScR guidelines. A comprehensive search will be performed across multiple databases, including PubMed, Embase, PsycINFO, and the Cochrane Library. Studies will be included if they involve individuals diagnosed with PTSD and evaluate prazosin as the therapeutic intervention. All study designs will be included. Animal studies and studies not assessing prazosin in the context of PTSD will be excluded. Title/abstract and full-text screening will be conducted independently by multiple reviewers, with conflicts resolved by a third reviewer. Data will be extracted on study characteristics, population details, intervention use, and reported outcomes.
Expected Significance: This review will provide a comprehensive review of the current literature on prazosin for PTSD, identify gaps in the literature, and inform future research and clinical practice.